1. Home
  2. Analysis
  3. Kenalog
  4. Requip

Kenalog and Requip drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Kenalog (triamcinolone acetonide) and Requip (ropinirole hydrochloride). Common drug interactions include fatigue among females and chronic kidney disease among males.

The phase IV clinical study analyzes what interactions people have when they take Kenalog and Requip. It is created by eHealthMe based on reports of 84 people who take the same drugs from the FDA, and is updated regularly.

What is Kenalog?

Kenalog has active ingredients of triamcinolone acetonide. It is often used in pain. eHealthMe is studying from 10,692 Kenalog users. Check the latest studies of Kenalog.

What is Requip?

Requip has active ingredients of ropinirole hydrochloride. It is often used in restless leg syndrome. eHealthMe is studying from 22,950 Requip users. Check the latest studies of Requip.

On Jul, 17, 2026

84 people who take Kenalog and Requip together, and have interactions are studied.

Kenalog and Requip drug interactions.

What are the common drug interactions of Kenalog and Requip, by gender? *:

female:

  1. Fatigue (feeling of tiredness)
  2. Diverticulum intestinal (a pouch that is attached to the first part of the small intestine)
  3. Colonic polyp (extra part of colon tissue grow in intestine)
  4. Constipation
  5. Foot deformity (functional disability of foot)
  6. Scoliosis (a medical condition in which a person's spine is curved from side to side)
  7. Dry mouth
  8. Hyperlipidaemia (presence of excess lipids in the blood)
  9. Musculoskeletal discomfort (discomfort in the body's muscles, joints, tendons, ligaments and nerves)
  10. Neuropathy peripheral (surface nerve damage)

male:

  1. Chronic kidney disease
  2. Blood creatinine increased
  3. Neoplasm malignant (cancer tumour)
  4. Skin swelling
  5. Asthenia (weakness)
  6. Cellulitis (infection under the skin)
  7. Colitis (inflammation of colon)
  8. Death
  9. Dehydration (dryness resulting from the removal of water)
  10. Diarrhoea

What are the common drug interactions of Kenalog and Requip, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Abdominal pain
  2. Abnormal weight gain
  3. Asthma
  4. Attention deficit/hyperactivity disorder
  5. Back pain
  6. Burning sensation
  7. Compulsive sexual behaviour (unable to manage his/her sexual behaviour)
  8. Compulsive shopping
  9. Cough
  10. Diarrhoea

20-29:

  1. Small intestinal obstruction (blockage in small intestine)
  2. Abdominal distension
  3. Abdominal pain
  4. Back pain
  5. Biliary dilatation
  6. Blood glucose decreased
  7. C-reactive protein increased
  8. Dizziness
  9. Dyspnoea (difficult or laboured respiration)
  10. Electrolyte imbalance

30-39:

  1. Anogenital warts
  2. Blood hiv rna increased
  3. Kidney infection
  4. Renal failure (kidney dysfunction)
  5. Viral load increased
  6. Anxiety
  7. Depression
  8. Humerus fracture (injury to the upper arm bone)
  9. Multiple fractures
  10. Tooth loss

40-49:

  1. Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
  2. Musculoskeletal pain (pain affects the bones, muscles, ligaments, tendons, and nerves)
  3. Neck pain

50-59:

  1. Vomiting
  2. Basal cell carcinoma (a skin cancer, it rarely metastasizes or kills)
  3. Drug ineffective
  4. Fall
  5. Limb crushing injury (crushing injury of upper limb)
  6. Night sweats (sweating in night)
  7. Pruritus generalised (generalized itching)
  8. Injection site pain
  9. Drug hypersensitivity
  10. Chronic kidney disease

60+:

  1. Hypertension (high blood pressure)
  2. Anxiety
  3. Hyperglycaemia (high blood sugar)
  4. Balance disorder
  5. Brain neoplasm (tumour of brain)
  6. Constipation
  7. Depression
  8. Dyspnoea (difficult or laboured respiration)
  9. Emotional distress
  10. Injury

What are the existing conditions these people have? *

  1. Neoplasm Malignant (cancer tumour): 22 people, 26.19%
  2. Metastases To Spine (cancer spreads to spine): 21 people, 25.00%
  3. Calcium Deficiency (lack of calcium): 21 people, 25.00%
  4. Lung Neoplasm (tumour of lung): 20 people, 23.81%
  5. Insomnia (sleeplessness): 16 people, 19.05%
  6. Nausea (feeling of having an urge to vomit): 15 people, 17.86%
  7. Stress And Anxiety: 13 people, 15.48%
  8. Constipation: 10 people, 11.90%
  9. Nausea And Vomiting: 10 people, 11.90%
  10. Vitamin D Decreased: 9 people, 10.71%

* Approximation only. Some reports may have incomplete information.

Do you take Kenalog and Requip?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Kenalog and Requip:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Kenalog:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Requip:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Kenalog and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Requip and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on triamcinolone acetonide and ropinirole hydrochloride (the active ingredients of Kenalog and Requip, respectively), and Kenalog and Requip (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.